Literature DB >> 9463483

Modulation of fluorouracil cytotoxicity by interferon-alpha and -gamma.

A Ismail1, C J Van Groeningen, A Hardcastle, Q Ren, G W Aherne, F Geoffroy, C J Allegra, J L Grem.   

Abstract

Because interferons (IFN)-alpha and -gamma individually have increased fluorouracil (FUra) cytotoxicity in several in vitro models, we studied the effects of FUra combined with IFN-alpha + gamma in HT29 colon cancer cells. A 96-hr exposure to IFN-alpha (500 units/ml) plus IFN-gamma (10 units/ml) and a 72-hr exposure to 0. 25-1 microM FUra (hr 24-96) inhibited cell growth and colony formation in an additive or more-than-additive fashion. When cells were exposed to IFN-alpha + gamma and FUra, free FdUMP levels became detectable, whereas [3H]FUra-RNA incorporation decreased. Exposure to IFN-alpha + gamma, FUra, or the combination decreased dTTP pools to 58%, 43%, and 17% of control, respectively. A marked increase in the dATP to dTTP ratio was seen with FUra with or without IFN-alpha + gamma. Thymidylate synthase catalytic activity was reduced to 28% and 24% of control with FUra with or without IFN-alpha + gamma, suggesting that the enhanced dTTP depletion must be due to another mechanism. FUra-mediated thymidylate synthase inhibition was accompanied by a 124-fold increase in total deoxyuridylate immunoreactivity and a 31-fold increase in dUTP pools, but the addition of IFN-alpha + gamma attenuated the accumulation. Treatment with IFN-alpha + gamma and FUra individually interfered with nascent DNA chain elongation, whereas the three-drug combination produced the most striking effects. IFN-alpha + gamma plus FUra produced the greatest amount of single-strand breaks in nascent DNA and dramatically decreased net DNA synthesis. IFN-alpha + gamma with or without FUra produced double-strand breaks in parental DNA. These results suggest that dTTP depletion, dATP/dTTP imbalance, pronounced inhibition of DNA synthesis, and damage to nascent and parental DNA contribute to the enhanced cytotoxicity with the triple combination.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9463483     DOI: 10.1124/mol.53.2.252

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  4 in total

1.  Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACOSOG Trial Z05031.

Authors:  V J Picozzi; R A Abrams; P A Decker; W Traverso; E M O'Reilly; E Greeno; R C Martin; L S Wilfong; M L Rothenberg; M C Posner; P W T Pisters
Journal:  Ann Oncol       Date:  2010-07-29       Impact factor: 32.976

2.  Oncolytic adenovirus expressing interferon alpha in a syngeneic Syrian hamster model for the treatment of pancreatic cancer.

Authors:  Christopher J LaRocca; Joohee Han; Tatyana Gavrikova; Leonard Armstrong; Amanda R Oliveira; Ryan Shanley; Selwyn M Vickers; Masato Yamamoto; Julia Davydova
Journal:  Surgery       Date:  2015-02-27       Impact factor: 3.982

Review 3.  5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development.

Authors:  J L Grem
Journal:  Invest New Drugs       Date:  2000-11       Impact factor: 3.850

Review 4.  Radiotherapy in Combination With Cytokine Treatment.

Authors:  Ondrej Palata; Nada Hradilova Podzimkova; Eva Nedvedova; Alexandra Umprecht; Lenka Sadilkova; Lenka Palova Jelinkova; Radek Spisek; Irena Adkins
Journal:  Front Oncol       Date:  2019-05-22       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.